Across TCGA pan-cancer cohorts, ONECUT3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ONECUT3 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher ONECUT3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ONECUT3 expression acts as an unfavorable survival marker.
THYM are the cancer types where ONECUT3 Mutation most reproducibly stratifies survival.